The Mask that Deactivates COVID-19 and its Variants in Under One Minute of Contact
Ultimate protection for you, your family & everyone!
Ultimate protection for you, your family & everyone!
Viracide’s proprietary coating deactivates 99%+ of Coronavirus in under 1-minute, plus Influenza in minutes!
Coming Soon!
Availability based on Regional Health Regulatory Certification
All the performance and protection of the Viracide 4-Ply Adult Mask in a reduced size, and perfect for children.
Coming Soon!
Availability based on Regional Health Regulatory Certification
All Viracide KN95 Masks (V-KN95 Mask) provides enhanced Nano filtration surpassing N95 standards with the added protection of Viracide full surface coating.
Coming Soon!
Availability based on Regional Health Regulatory Certification
Viracide’s proprietary coating deactivates 99%+ of Coronavirus in under 1-minute, plus Influenza in minutes!
All the performance and protection of the Viracide 4-Ply Adult Mask in a reduced size, and perfect for children.
All Viracide KN95 Masks (V-KN95 Mask) provide enhanced filtration surpassing N95 standards with the added protection of Viracide full surface coating.
Viracide Masks are the ONLY face Covering masks in the market that DEACTIVATES Coronavirus in under 1-minute, plus Influenza in minutes. Verified by third-party test labs.
Standard Mask | Viracide Mask -V4 | ||
Deactivates 99% of Coronavirus & Influenza in Minutes | No | Yes | |
Antibacterial Shield | No | Yes | |
Enhanced Filtration | No | Yes | |
Proprietary Homeopathic Scent | No | Yes | |
Individually Wrapped for Safety | No | Yes | |
Disposable | Yes | Yes |
V4 Viracide Masks are produced in an FDA Registered Factory and an ISO 9001 & ISO 13485 certified factory to uphold maximum quality standards. This mask is currently in an active review by the FDA for premarket certification and 510k authorization with parallel CE review and certification now in process. Though filtration is greater than N95 standards the V4 is not a substitute for N95. Virus Deactivation Testing provided by FDA approved Situ BioScience Labs USA and Filtration testing provided by 3rd Party Test Labs.
Adult Mask Shipping Specifications
One (1) product box has 30 masks
One (1) carton has 50 product boxes = 1,500 masks
One (1) pallet has 12 cartons (3 cartons high) = 18,000 masks
One (1) 40 ft. container = 50 pallets = 900,000 masks
Barcode | DESCRIPTION | AVAILABILITY | ||
1 | 00850003773421 | 30 Count | 1st Quarter 2022 | 1st Quarter 2022 |
2 | 10850003773428 | 1,500 count | 1st Quarter 2022 | 1st Quarter 2022 |
Viracide’s V-KN95 includes all the same Coronavirus and Influenza deactivating features as the Viracide 4-Ply masks, supplying the same protection and comfort of traditional N95 masks on the market with enhanced protection.
Coming Soon!
Availability based on Regional Health Regulatory Certification
Standard N95 Mask | Viracide Mask-V-KN95 | ||
Deactivates 99% of Coronavirus & Influenza in Minutes | No | Yes | |
Antibacterial Shield | No | Yes | |
Enhanced Filtration | Yes | Yes | |
Proprietary Homeopathic scent | No | Yes | |
Individually Wrapped for Safety | No | Yes | |
Disposable | Yes | Yes |
Dr. Marya Ghazipura is a renowned epidemiologist and biostatistician formally at New York University Langone Health. She currently serves on the NYC COVID-19 Scientific Advisory Council, and collaborates with and consults in a number of industries, including numerous international medical societies, government agencies such as NASA and the Canadian Ministry of Health, and large pharmaceutical companies. Dr. Ghazipura developed an epidemiological model to assess how the introduction of a mask with significant viral-killing properties, as well as a reliable 95%+ high filtration-rate would affect the present infection rate of COVID-19 in each U.S. state. This model was constructed based on present mask adherence and transmissibility rates by state, assessing how the number of new cases per day (both confirmed and predicted) will be impacted upon adoption of these masks.
Her conclusions, based on her modeling criteria, are as follows:
80% of states (40 states) will be able to reduce their number of new cases per day by 50% in 100 days or less.
92% of states (46 states) will be able to reduce their number of new cases per day by 50% in 300 days or less.
*Marya Ghazipura, PhD, MS
Epidemiologist and Biostatistician
Formerly at NYU Langone Health
NYC COVID-19 Scientific Advisory Council
Corporate Headquarters
630 9th Ave, Suite 1411
New York, NY 10036
Research Center
107 Woody Drive
Butler, PA 16001
© 2022 Vitiprints, LLC. All Rights Reserved. Terms of Service • Privacy Policy